Vijaya Diagnost.

Why is Vijaya Diagnostic Centre Ltd falling/rising?

As of 04-Aug, Vijaya Diagnostic Centre Ltd's stock price is rising to Rs 1,384.15, driven by strong performance indicators, increased investor participation, and positive financial metrics. The stock is trading above key moving averages and is close to its 52-week high, reflecting robust market interest and confidence.

As of 04-Aug, Vijaya Diagnostic Centre Ltd's stock price is rising, currently at Rs 1,384.15, reflecting an increase of Rs 34.7 or 2.57%. This upward movement can be attributed to several factors. The stock has shown a consistent performance, gaining 3.07% over the last two days and outperforming its sector by 1.54% today. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Investor participation has also increased significantly, with a delivery volume of 2.76 lakh shares on August 3, which is up by 263.01% compared to the 5-day average. This surge in trading activity suggests heightened interest among investors. Furthermore, the stock is close to its 52-week high, being only 4.13% away from Rs 1,440, which may encourage more buying as investors anticipate reaching this peak.<BR><BR>The company's strong financial performance, highlighted by record net sales and profitability in the latest quarter, along with a high return on capital employed (ROCE) of 22.48% and a low debt-to-equity ratio of 0.09, further supports the stock's positive momentum. High institutional holdings at 43.26% indicate confidence from more sophisticated investors, which can also contribute to the stock's rising price. Overall, these factors collectively contribute to the upward trajectory of Vijaya Diagnostic Centre Ltd's stock price.

Which are the latest news on Vijaya Diagnost.?

Should I buy, sell or hold Vijaya Diagnostic Centre Ltd?

What does Vijaya Diagnost. do?

Vijaya Diagnostic Centre Ltd is a leading diagnostic services provider in Southern India, established in 1981, with recent net sales of 219 Cr and a net profit of 48 Cr as of March 2026. It has a market cap of INR 13,302 Cr and key metrics include a P/E ratio of 76.00 and a return on equity of 18.07%.

Overview: <BR>Vijaya Diagnostic Centre Ltd is a leading provider of diagnostic services in the healthcare services industry, categorized as a small-cap company.<BR><BR>History: <BR>Incorporated in 1981, Vijaya Diagnostic Centre has established itself as the largest integrated diagnostic chain in Southern India. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 219 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 48 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 13,302 Cr (Small Cap) <BR><BR>Key Metrics: <BR>P/E: 76.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.15% <BR>Debt-Equity: 0.15 <BR>Return on Equity: 18.07% <BR>Price to Book: 13.96 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Vijaya Diagnost.?

As of 10th June, Vijaya Diagnostic Centre Ltd has a market capitalization of 13,302.00 Cr, with recent net sales of 814.20 Cr and net profit of 172.98 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Vijaya Diagnostic Centre Ltd has a market capitalization of 13,302.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 814.20 Cr, while the sum of Net Profit for the same period is 172.98 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 795.71 Cr and Total Assets valued at 1,273.62 Cr.

Who are in the management team of Vijaya Diagnost.?

The management team of Vijaya Diagnost includes Sura Surendranath Reddy (Chairman & Executive Director), Sura Suprita Reddy (Managing Director & CEO), and several independent and non-executive directors, such as Geeta Reddy and C S N Murthy. This diverse team guides the company's governance and strategy.

The management team of Vijaya Diagnost includes the following individuals:<BR><BR>1. **Sura Surendranath Reddy** - Chairman & Executive Director<BR>2. **Sunil Chandra Kondapally** - Executive Director<BR>3. **Geeta Reddy** - Non-Executive & Non-Independent Director<BR>4. **C S N Murthy** - Independent Non-Executive Director<BR>5. **DUVVURU NAGESHWAR REDDY** - Independent Non-Executive Director<BR>6. **SEKHAR PRASAD SINGH** - Independent Non-Executive Director<BR>7. **Manjula Anagani** - Independent Non-Executive Director<BR>8. **Sura Suprita Reddy** - Managing Director & CEO<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

Who are the peers of the Vijaya Diagnost.?

Vijaya Diagnost.'s peers include Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost. Among these, Vijaya Diagnost. shows good growth and the highest 1-year return at 36.39%, while Syngene Intl. has the lowest return at -31.36%.

Peers: The peers of Vijaya Diagnost. are Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech. Average management risk is noted at Indegene and Vimta Labs, and the rest have Below Average management risk, including Suven Life Scie. and Krsnaa Diagnost. All peers exhibit Below Average growth, except for Vijaya Diagnost., which also has Good growth. Excellent capital structure is seen at Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Average capital structure is noted at Vimta Labs and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vijaya Diagnost. at 36.39%, while the lowest is Syngene Intl. at -31.36%. Vijaya Diagnost.'s return is significantly higher than all peers. Additionally, Indegene, Suven Life Scie., and Krsnaa Diagnost. have negative six-month returns.

Are Vijaya Diagnostic Centre Ltd latest results good or bad?

Vijaya Diagnostic Centre Ltd's latest results are strong, with a net profit increase of 37.49% year-on-year and revenue growth of 26.63%. However, the high P/E ratio of 77.0x raises concerns about sustainability, suggesting caution for potential investors.

Vijaya Diagnostic Centre Ltd's latest results for the quarter ending March 2026 indicate a strong performance overall. The company reported a net profit of ₹47.93 crores, which represents a significant year-on-year increase of 37.49% and an 11% increase compared to the previous quarter. Additionally, revenue reached ₹219.38 crores, marking a year-on-year growth of 26.63% and a sequential growth of 6.91%. <BR><BR>The operating margin also improved to 43.54%, the highest in seven quarters, reflecting effective cost management and operational efficiency. These metrics suggest that the company is experiencing robust demand and is effectively capitalizing on the growing healthcare awareness in India.<BR><BR>However, it's important to note that the stock is currently trading at a high valuation, with a P/E ratio of 77.0x, which is considered expensive compared to its peers. This premium valuation raises concerns about whether the company's growth can sustain such high expectations.<BR><BR>In summary, while the operational results are strong and indicate good financial health, the elevated valuation may warrant caution for potential investors.

Is Vijaya Diagnost. technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by bullish indicators like the MACD and Bollinger Bands, though caution is advised due to some lingering bearish signals.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly chart and bullish Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish trend. However, the monthly MACD and KST remain mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish stance on both weekly and monthly charts, while the On-Balance Volume is mildly bearish, indicating mixed signals. Overall, the strength of the bullish trend is tempered by some bearish indicators, but the shift to mildly bullish suggests potential for further upside.

How has been the historical performance of Vijaya Diagnost.?

Vijaya Diagnost has shown consistent growth over the past five years, with net sales increasing from 376.75 Cr in Mar'21 to 681.39 Cr in Mar'25, and profit after tax rising from 85.13 Cr to 143.79 Cr in the same period, indicating strong operational efficiency and financial performance.

Answer:<BR>The historical performance of Vijaya Diagnost shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Vijaya Diagnost's net sales have increased from 376.75 Cr in Mar'21 to 681.39 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising to 681.39 Cr in Mar'25 from 459.22 Cr in Mar'23. The total expenditure, excluding depreciation, also grew, reaching 408.17 Cr in Mar'25, up from 210.77 Cr in Mar'21. Operating profit (PBDIT) saw a significant rise, reaching 291.54 Cr in Mar'25 compared to 177.83 Cr in Mar'21, indicating improved operational efficiency. Profit before tax increased to 193.16 Cr in Mar'25 from 112.12 Cr in Mar'21, while profit after tax rose to 143.79 Cr from 85.13 Cr in Mar'21. The earnings per share (EPS) also improved significantly, reaching 14.01 in Mar'25 from 3.68 in Mar'21. On the balance sheet, total assets grew to 1,273.62 Cr in Mar'25 from 480.68 Cr in Mar'20, while total liabilities increased to 1,273.62 Cr from 480.68 Cr in Mar'20, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved to 224.00 Cr in Mar'25 from 106.00 Cr in Mar'20, although net cash outflow was recorded at -9.00 Cr in Mar'25. Overall, Vijaya Diagnost has demonstrated robust growth in sales, profits, and operational cash flow over the years.

Who are the top shareholders of the Vijaya Diagnost.?

The top shareholders of Vijaya Diagnost include promoters holding the majority, with Surendranath Reddy Sura as the largest individual shareholder at 32.3%. Mutual funds hold 23.55%, foreign institutional investors 19.56%, and the highest public shareholder is Nippon Life India Trustee Ltd at 5.82%.

The top shareholders of Vijaya Diagnost include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority of the shares are held by promoters, with Surendranath Reddy Sura being the largest individual shareholder, holding 32.3%. Mutual funds collectively hold 23.55% of the shares, while FIIs account for 19.56%. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 5.82%. Additionally, individual investors have a stake of 3.24%.

Is Vijaya Diagnost. overvalued or undervalued?

As of August 1, 2022, Vijaya Diagnostics is considered very expensive and overvalued with a PE ratio of 69.56 and an EV to EBITDA of 36.94, trading at higher valuations than peers like Apollo Hospitals and Fortis Healthcare, despite outperforming the Sensex over the past year.

As of 1 August 2022, the valuation grade for Vijaya Diagnostics has moved from expensive to very expensive. The company is currently considered overvalued based on its high valuation metrics. Key ratios include a PE ratio of 69.56, an EV to EBITDA of 36.94, and a PEG ratio of 3.63, all of which indicate a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals Enterprise Ltd. has a PE ratio of 69.03 and an EV to EBITDA of 34.71, while Fortis Healthcare Ltd. shows a PE ratio of 68.71 and an EV to EBITDA of 37.55. These comparisons highlight that Vijaya Diagnostics is trading at a higher valuation than its peers in the healthcare services sector. Although the stock has outperformed the Sensex over the past year with a return of 19.95% compared to the Sensex's 7.55%, the overall valuation suggests that the stock is not a favorable investment at this time.

When is the next results date for Vijaya Diagnost.?

No Upcoming Board Meetings

Has Vijaya Diagnost. declared dividend?

Yes, Vijaya Diagnostic Centre Ltd has declared a 100% dividend of ₹1 per share, with an ex-date of August 30, 2024. While the company has shown varying price returns over different periods, dividend returns have been relatively low.

Yes, Vijaya Diagnostic Centre Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 1<BR>- Ex-date: 30 Aug 2024<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -14.85%, the dividend return was 0%, resulting in a total return of -14.85%.<BR><BR>For the 1 year period, the price return was 19.05%, the dividend return was 0.12%, leading to a total return of 19.17%.<BR><BR>Over the 2 years period, the price return was 152.02%, the dividend return was 0.49%, which resulted in a total return of 152.51%.<BR><BR>In the 3 years period, the price return was 182.45%, the dividend return was 0.90%, culminating in a total return of 183.35%.<BR><BR>For the 4 years period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>In the 5 years period, there was also no change in price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Vijaya Diagnostic Centre Ltd has declared a dividend, the dividend returns over various periods have been relatively low compared to the price returns, indicating that while there is a dividend, the company's performance has varied significantly over time.